Skip to main content
. 2020 Sep 15;2(3):385–396. doi: 10.1016/j.jaccao.2020.07.008

Central Illustration.

Central Illustration

Cumulative Incidence Rates for the Primary Malignancy Endpoint by Treatment Arm

Simvastatin/ezetimibe (red) and placebo/ezetimibe (blue). The primary malignancy endpoint was defined as new, relapsing, or progressive malignancy (excluding nonmelanotic skin malignancy). The cumulative incidence plots were presented graphically using Kaplan-Meier product-limit method. CI = confidence interval; HR = hazard ratio.